4 C Medical Technologies
Biotechnology, 6655 Wedgwood Rd N Ste 160, Maple Grove, Minnesota, 55311, United States, 11-50 Employees
Phone Number: 16*********
Who is 4C MEDICAL TECHNOLOGIES
4C Medical Technologies, Inc. is a medical device company developing a novel minimally invasive solution for the treatment of mitral regurgitation (MR). We are the first transcatheter MR ...
Read More
-
Headquarters: 6655 Wedgwood Rd N Ste 160, Maple Grove, Minnesota, 55311, United States
-
Date Founded: 2016
-
Employees: 11-50
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 3841
|
NAICS Code: 339112 |
Show More
Does something look wrong? Fix it. | View contact records from 4C MEDICAL TECHNOLOGIES
4C Medical Technologies Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding 4C Medical Technologies
Answer: 4C Medical Technologies's headquarters are located at 6655 Wedgwood Rd N Ste 160, Maple Grove, Minnesota, 55311, United States
Answer: 4C Medical Technologies's phone number is 16*********
Answer: 4C Medical Technologies's official website is https://4cmed.com
Answer: 4C Medical Technologies's revenue is $10 Million to $25 Million
Answer: 4C Medical Technologies's SIC: 3841
Answer: 4C Medical Technologies's NAICS: 339112
Answer: 4C Medical Technologies has 11-50 employees
Answer: 4C Medical Technologies is in Biotechnology
Answer: 4C Medical Technologies contact info: Phone number: 16********* Website: https://4cmed.com
Answer: 4C Medical Technologies, Inc. is a medical device company developing a novel minimally invasive solution for the treatment of mitral regurgitation (MR). We are the first transcatheter MR therapy that directly addresses mitral regurgitation without replacing the native mitral valve, thus preserving the native mitral annulus and left ventricle. The device is positioned supra annular to the leaking native mitral valve to stop the leak from entering the left atrium. Its atrial only fixation ensures minimal disruption to critical cardiac structures within the left ventricle including the chordae tendineae and the left ventricular outflow tract. Our initial focus is to develop a novel therapy for mitral regurgitation (MR), and subsequently for tricuspid regurgitation (TR).
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month